- Reuters•17 minutes ago
U.S. biotechnology company Celgene Corp reported a better-than-expected quarterly profit and raised its adjusted earnings forecast for 2016 due to higher demand for its key multiple myeloma drug, Revlimid. ...
- TheStreet.com•23 minutes ago
Celgene posted second-quarter earnings which exceeded analyst consensus expectations by a small margin but enough to raise guidance for the remainder of the year.
Pre-Market: 109.501.39 (1.29%) as of 8:22 AM EDT
|Bid||108.00 x 600|
|Ask||108.29 x 100|
|52wk Range||92.98 - 133.59|
|Day's Range||105.57 - 108.84|
|Avg Vol (3m)||4,389,412|
As of 4:00 PM EDT. Market closed.